[144] Roivant Sciences Ltd. SEC Filing

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) Form 144 notifies proposed sale of 100,000 common shares to be executed on 08/20/2025 through Rockefeller Financial LLC on NASDAQ, with an aggregate market value listed as $1,172,120.12. The shares were shown as acquired by exercise of options on 08/20/2025 (grant date 04/20/2022) from Roivant Sciences Ltd., with payment by wire. The filer also disclosed multiple recent sales by Eric Venker totaling 1,330,148 shares between 05/20/2025 and 07/21/2025 with gross proceeds reported for each transaction.

Positive

• None.

Negative

• Repeated large insider sales: 1,330,148 shares sold in recent months and a proposed 100,000-share sale could increase supply and pressure price liquidity.
• No 10b5-1 plan date disclosed: Filing does not indicate a trading-plan adoption date for the proposed sale, which may limit clarity on whether sales are pre-planned.

Insights

Financial Analyst

TL;DR Insider has sold and plans to sell material share blocks recently; this is a notable liquidity event but not a statement on fundamentals.

The Form 144 shows a proposed 100,000-share sale valued at $1.17M and documents prior sales by the same person totaling 1,330,148 shares across May–July 2025 with proceeds reported per trade. From a market-impact perspective, concentrated insider selling of this magnitude can increase share supply in the market and potentially pressure near-term price liquidity depending on overall float and trading volume. The filing states the shares to be sold were acquired via option exercise on the same date as the proposed sale and funded by wire, indicating immediate monetization of newly acquired shares rather than long-term retention.

Corporate Governance Expert

TL;DR Multiple disclosures indicate routine Rule 144 compliance for insider sales; disclosure itself is standard but warrants attention.

The notice adheres to Rule 144 reporting by identifying broker, sale date, and acquisition details. The filer attests no undisclosed material nonpublic information. Repeated large sales by a named individual are governance-relevant for stakeholders assessing insider alignment with shareholders. The filing does not state any 10b5-1 plan adoption date or other prearranged trading-plan detail, so readers should note the absence of that disclosure in this document.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	100000	1172120.12	682881743	08/20/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	08/20/2025	Options Exercise - Grant Date 4/20/2022	Roivant Sciences Ltd.			100000	08/20/2025	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common shares	07/21/2025	100000	1151941.91
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway,, London X0 SW1HODB	Common Stock	06/03/2025	566278	6353639.16
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	06/02/2025	433722	4801302.54
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common Shares	06/20/2025	100000	1145268.08
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway,, London X0 SW1HODB	Common Shares	05/20/2025	39148	432193.92
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	05/20/2025	100000	1094985.82

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is being reported in the ROIV Form 144?

The filing reports a proposed sale of 100,000 common shares to occur on 08/20/2025 via Rockefeller Financial LLC on NASDAQ with aggregate market value of $1,172,120.12.

Who is the person associated with the recent sales disclosed?

Recent sales listed in the filing were by Eric Venker (c/o Roivant Sciences Ltd.), showing multiple transactions between 05/20/2025 and 07/21/2025.

How many shares were sold in prior transactions and what were the proceeds?

Prior transactions total 1,330,148 shares across six listed sales, with individual gross proceeds reported for each trade in the filing.

How were the shares being offered for sale acquired?

The 100,000 shares to be sold were acquired by options exercise on 08/20/2025 (grant date 04/20/2022), and the payment method for purchase was listed as wire.

Does the filing state the seller possesses any undisclosed material information?

By signing the notice, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.